Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ)
Chitosan oligosaccharides (COS) display various biological activities. In this study, we aimed to explore the preventive effects of COS on glucolipid metabolism disorder using palmitic acid (PA)-induced HepG2 cells and high-fat diet (HFD)-fed C57BL/6J mice as experimental models in vitro and in vivo...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-11-01
|
Series: | Marine Drugs |
Subjects: | |
Online Access: | https://www.mdpi.com/1660-3397/16/11/455 |
id |
doaj-15244b10ef3c4737ba650fb809839772 |
---|---|
record_format |
Article |
spelling |
doaj-15244b10ef3c4737ba650fb8098397722020-11-24T20:56:11ZengMDPI AGMarine Drugs1660-33972018-11-01161145510.3390/md16110455md16110455Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ)Yibo Bai0Junping Zheng1Xubing Yuan2Siming Jiao3Cui Feng4Yuguang Du5Hongtao Liu6Lanyan Zheng7Department of Pathogen Biology, College of Basic Medical Sciences, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang 110122, ChinaState Key Laboratory of Biochemical Engineering and Key Laboratory of Biopharmaceutical Production & Formulation Engineering, PLA, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, ChinaState Key Laboratory of Biochemical Engineering and Key Laboratory of Biopharmaceutical Production & Formulation Engineering, PLA, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, ChinaState Key Laboratory of Biochemical Engineering and Key Laboratory of Biopharmaceutical Production & Formulation Engineering, PLA, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, ChinaState Key Laboratory of Biochemical Engineering and Key Laboratory of Biopharmaceutical Production & Formulation Engineering, PLA, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, ChinaState Key Laboratory of Biochemical Engineering and Key Laboratory of Biopharmaceutical Production & Formulation Engineering, PLA, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, ChinaState Key Laboratory of Biochemical Engineering and Key Laboratory of Biopharmaceutical Production & Formulation Engineering, PLA, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, ChinaDepartment of Pathogen Biology, College of Basic Medical Sciences, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang 110122, ChinaChitosan oligosaccharides (COS) display various biological activities. In this study, we aimed to explore the preventive effects of COS on glucolipid metabolism disorder using palmitic acid (PA)-induced HepG2 cells and high-fat diet (HFD)-fed C57BL/6J mice as experimental models in vitro and in vivo, respectively. The results showed that COS pretreatment for 12 h significantly ameliorated lipid accumulation in HepG2 cells exposed to PA for 24 h, accompanied by a reversing of the upregulated mRNA expression of proinflammatory cytokines (IL-6, MCP-1, TNF-α) and glucolipid metabolism-related regulators (SCD-1, ACC1, PCK1-α). In addition, COS treatment alleviated glucolipid metabolism disorder in mice fed with HFD for five months, including reduction in body weight and fasting glucose, restoration of intraperitoneal glucose tolerance, and suppression of overexpression of proinflammatory cytokines and glucolipid metabolism-related regulators. Furthermore, our study found that COS pretreatment significantly reversed the downregulation of PPARγ at transcriptional and translational levels in both PA-induced HepG2 cells and liver tissues of HFD-fed mice. In summary, the study suggests that COS can improve glucolipid metabolism disorder by suppressing inflammation and upregulating PPARγ expression. This indicates a novel application of COS in preventing and treating glucolipid metabolism-related diseases.https://www.mdpi.com/1660-3397/16/11/455chitosan oligosaccharideglucolipid metabolism disorderhigh-fat dietinflammationperoxisome proliferator-activated receptor gamma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yibo Bai Junping Zheng Xubing Yuan Siming Jiao Cui Feng Yuguang Du Hongtao Liu Lanyan Zheng |
spellingShingle |
Yibo Bai Junping Zheng Xubing Yuan Siming Jiao Cui Feng Yuguang Du Hongtao Liu Lanyan Zheng Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Marine Drugs chitosan oligosaccharide glucolipid metabolism disorder high-fat diet inflammation peroxisome proliferator-activated receptor gamma |
author_facet |
Yibo Bai Junping Zheng Xubing Yuan Siming Jiao Cui Feng Yuguang Du Hongtao Liu Lanyan Zheng |
author_sort |
Yibo Bai |
title |
Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) |
title_short |
Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) |
title_full |
Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) |
title_fullStr |
Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) |
title_full_unstemmed |
Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) |
title_sort |
chitosan oligosaccharides improve glucolipid metabolism disorder in liver by suppression of obesity-related inflammation and restoration of peroxisome proliferator-activated receptor gamma (pparγ) |
publisher |
MDPI AG |
series |
Marine Drugs |
issn |
1660-3397 |
publishDate |
2018-11-01 |
description |
Chitosan oligosaccharides (COS) display various biological activities. In this study, we aimed to explore the preventive effects of COS on glucolipid metabolism disorder using palmitic acid (PA)-induced HepG2 cells and high-fat diet (HFD)-fed C57BL/6J mice as experimental models in vitro and in vivo, respectively. The results showed that COS pretreatment for 12 h significantly ameliorated lipid accumulation in HepG2 cells exposed to PA for 24 h, accompanied by a reversing of the upregulated mRNA expression of proinflammatory cytokines (IL-6, MCP-1, TNF-α) and glucolipid metabolism-related regulators (SCD-1, ACC1, PCK1-α). In addition, COS treatment alleviated glucolipid metabolism disorder in mice fed with HFD for five months, including reduction in body weight and fasting glucose, restoration of intraperitoneal glucose tolerance, and suppression of overexpression of proinflammatory cytokines and glucolipid metabolism-related regulators. Furthermore, our study found that COS pretreatment significantly reversed the downregulation of PPARγ at transcriptional and translational levels in both PA-induced HepG2 cells and liver tissues of HFD-fed mice. In summary, the study suggests that COS can improve glucolipid metabolism disorder by suppressing inflammation and upregulating PPARγ expression. This indicates a novel application of COS in preventing and treating glucolipid metabolism-related diseases. |
topic |
chitosan oligosaccharide glucolipid metabolism disorder high-fat diet inflammation peroxisome proliferator-activated receptor gamma |
url |
https://www.mdpi.com/1660-3397/16/11/455 |
work_keys_str_mv |
AT yibobai chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg AT junpingzheng chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg AT xubingyuan chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg AT simingjiao chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg AT cuifeng chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg AT yuguangdu chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg AT hongtaoliu chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg AT lanyanzheng chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg |
_version_ |
1716790445977108480 |